PATENT CLAIM ANALYSIS

Application Number: 15892265
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["424", "093210"]

Abstract:
Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×10 8  infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.

Claim (Index 15):
The method of  claim 1 , wherein said vaccinia virus comprises one or more modified viral genes selected from the group consisting of:\n (a) an interferon-modulating polypeptide; (b) a complement control polypeptide; (c) a TNF or chemokine-modulating polypeptide; (d) a serine protease inhibitor; (e) a IL-1\u03b2 modulating polypeptide; a non-infectious EEV form polypeptide; and (g) a viral polypeptide that act to inhibit release of infectious virus from cells (anti-infectious virus form polypeptide).

Metadata:
- Claim Count in Document: 50.0
- Percentile: 88.0
- Lexical Diversity: 1.65306
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13535291', '14656397', '14876195', '11470951', '15892247']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7537382160817143
- 35 USC 102 Novelty (BERT): 0.5986390490315997
- Combined Prediction Score: 0.7382282993767029
- Mean Citation Score: 493.250046
- Max Citation Score: 541.0012
- Similarity Product: 443.39345105369097

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test